Clinical Significance of Circulating Tumour Cells in Resectable Lung Cancer Patients
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 166
- 试验地点
- 1
- 主要终点
- CEA, EGFR, LunX, c-met and EpCAM mRNA positive circulating tumour cells in lung cancer patients
研究概览
简要总结
To determine whether the presence of circulating/disseminated tumour cells (CTCs/DTCs) in the blood and bone marrow of the resectable lung cancer (NSCLC) patients is a negative prognostic factor, and to find correlations with other clinical/pathological disease characteristics.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Non-small cell lung cancer, non-metastatic
排除标准
- •Prior neoadjuvant chemoradiotherapy Prior lung cancer Cancer duplicity
结局指标
主要结局
CEA, EGFR, LunX, c-met and EpCAM mRNA positive circulating tumour cells in lung cancer patients
时间窗: 30 days
The absolute gene expression of CEA, EGFR, LunX, c-met and EpCAM mRNA positive circulating tumour cells(CTCs) isolated from peripheral blood, tumour draining blood and bone marrow samples of lung cancer patients will be measured using real-time RT-PCR method. The gene expression will be normalized per microgram of total mRNA.
次要结局
- Cancer specific survival in CTC positive NSCLC patients(5 years)
研究者
Marian Hajduch, M.D., Ph.D.
IMTM director
The Institute of Molecular and Translational Medicine, Czech Republic